Testing vimseltinib for chronic graft versus host disease
Part of Digestive system, Immune system & allergy, Infections, Lungs & breathing clinical trials.
This trial tests a new drug called vimseltinib for people with active chronic graft versus host disease (cGVHD) that hasn't gotten better after at least two prior treatments. The goal is to see if vimseltinib can help control the condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a stem cell transplant from a donor and now have moderate to severe chronic GVHD that needs immune suppression medicines.
- You have already tried at least two different treatments for cGVHD and they haven't worked well enough.
- If you take steroids, your dose must have been stable for at least two weeks before starting the study drug.
- Your overall health and organ function must be good enough to safely participate.
- You have not taken a CSF1R inhibitor (a type of targeted medicine) for cGVHD before.
- You do not have any other serious illness, uncontrolled infection, or wounds that are not healed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatments, ruxolitinib and prednisone, as the first therapy for chronic graft-versus-host disease (cGVHD), a condition where donor cells attack your body after a stem cell transplant. The goal is to see which medicine works better and has fewer side effects.
This trial tests whether the drug ruxolitinib, given based on a blood test that predicts risk, can prevent chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It may help people who have a higher risk of developing this complication.
This trial tests a new pill called rovadicitinib for chronic GVHD that has not improved after 2 to 5 other treatments. It compares the new drug to one chosen by your doctor from a list of approved options.
This early-phase study tests pacritinib, a targeted medicine, for chronic graft-versus-host disease (cGVHD) that hasn’t improved after prior treatments. If you qualify, the goal is to reduce cGVHD symptoms and improve how well you function after a stem cell transplant.
This trial tests a new drug, gecacitinib, for patients with moderate to severe chronic graft-versus-host disease (cGVHD) that has not improved after 2 to 5 prior treatments. It aims to see if the drug is safe and effective.
This trial tests an experimental drug called Iguratimod for people with chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It aims to see if the drug can safely control cGVHD symptoms when other treatments haven't worked well enough.
Hear when a new Chronic Graft-Versus-Host Disease (cGVHD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.